Seasoned tech CEO Spiegelberg appointed to drive Doctorlink’s expansion
Doctorlink, the UK’s leading online health and symptom assessment platform for the NHS, has appointed Rupert Spiegelberg as its new Chief Executive Officer.
Doctorlink currently provides 24/7 access to digital symptom assessment to more than 10 million NHS patients across 1,350 GP practices; Rupert’s mission is to build on the success in the NHS by taking the Doctorlink platform global, to public and private healthcare providers around the world.
Doctorlink was founded in 2017 by Eight Roads, a global investment company backed by Fidelity with a 50-year history of leading and growing international tech companies.
“The benefits in improving patient access to healthcare, shortening waiting times and helping NHS England to save costs makes it a very compelling proposition for primary healthcare providers and insurers,” said Rupert Spiegelberg, CEO at Doctorlink.
He continued: “Our Symptom Assessment product has been proven to reduce the demand on NHS GPs by more than 20% as well as take pressure off A&E departments. We now want to bring that transformation to patients and providers across the world.”
Doctorlink’s Symptom Assessment, developed over 18 years by a team of expert clinicians, is classified as a Class 1 Medical Equipment device by the Medicines and Healthcare products Regulatory Agency. Its outcomes are sufficiently accurate to be fully indemnified, enabling the technology to be selected by one of the world’s most trusted health services – the NHS..
Rupert is a technology industry veteran who was most recently CEO of the Munich-based AI-powered digital identity company IDNow, tripling its size over two years and expanding its footprint beyond Germany to multiple European countries.
Prior to that, Spiegelberg was CEO of Investis Inc in New York, a global SaaS communications platform that helped Fortune 500 and other listed companies meet their online regulatory disclosure requirements.
Rupert succeeds former Doctorlink CEO and founder, Andrew Gardner, who will remain as a special advisor to the Board.
